Merck KGaA (FRA:MRK)
Germany
· Delayed Price · Currency is EUR 116.40
+0.45 (0.39%)
At close: Jun 11, 2025, 10:00 PM CET
Merck KGaA Employees
Merck KGaA had 59,020 employees as of December 31, 2024. The number of employees decreased by 3,888 or -6.18% compared to the previous year.
Employees
59,020
Change (1Y)
-3,888
Growth (1Y)
-6.18%
Revenue / Employee
€340,489
Profits / Employee
€45,013
Market Cap
50.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59,020 | -3,888 | -6.18% |
| Dec 31, 2023 | 62,908 | -1,324 | -2.06% |
| Dec 31, 2022 | 64,232 | 3,898 | 6.46% |
| Dec 31, 2021 | 60,334 | 2,207 | 3.80% |
| Dec 31, 2020 | 58,127 | 1,056 | 1.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Allianz SE | 156,626 |
| Rheinmetall AG | 28,539 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Siemens Energy AG | 98,000 |
| Deutsche Börse AG | 15,495 |
Merck KGaA News
- 2 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 2 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 2 days ago - China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 6 days ago - EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 8 days ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Wallstreet:Online
- 14 days ago - Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor - Benzinga
- 16 days ago - Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country - Business Upturn
- 21 days ago - EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash - Benzinga